Zegalogue (dasiglucagon) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 0 Diseases   6 Trials   6 Trials   152 News 


1234»
  • ||||||||||  Zegalogue (dasiglucagon) / Novo Nordisk
    Journal:  Glucose-Driven Droplet Formation in Complexes of a Supramolecular Peptide and Therapeutic Protein. (Pubmed Central) -  Mar 11, 2024   
    These droplets also offer function in mitigating the most severe effects of hypoglycemia arising from an insulin overdose through delivery of dasiglucagon in a mouse model of hypoglycemic rescue. Accordingly, this approach to use complexation between a supramolecular peptide amphiphile and a therapeutic protein in the presence of glucose leads to droplets with functional potential to dissipate for the release of the therapeutic material in low blood glucose environments.
  • ||||||||||  GlucaGen (recombinant glucagon) / Novo Nordisk, Zegalogue (dasiglucagon) / Novo Nordisk
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  STABLE-1: A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System (clinicaltrials.gov) -  Jan 2, 2024   
    P2,  N=0, Withdrawn, 
    While the BIM does not account for dasiglucagon N=12 --> 0 | Trial completion date: Aug 2023 --> Dec 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2023 --> Dec 2023
  • ||||||||||  Zegalogue (dasiglucagon) / Novo Nordisk
    Retrospective data, Journal:  Dasiglucagon for the Treatment of Insulin-induced Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Meta-analysis. (Pubmed Central) -  Sep 22, 2023   
    The time to recovery (in minutes) with dasiglucagon was earlier than placebo [mean difference (MD): -24.73; 95% confidence interval (CI): -30.94 to -18.52; p < 0.00001) or oral glucose (MD: -15.00; 95% CI: -20.33 to -9.67; p < 0.00001); however, the difference between dasiglucagon and glucagon was not statistically significant (MD: -0.76; 95% CI: -2.19 to 0.66; p = 0.29). Dasiglucagon is safer and more effective than placebo or oral glucose for insulin-induced hypoglycemia in T1DM patients; however, it is not superior to conventional glucagon.
  • ||||||||||  Baqsimi (glucagon intranasal dry powder) / Amphastar, Zegalogue (dasiglucagon) / Novo Nordisk, Gvoke HypoPen (glucagon auto-injectable rescue pen) / Xeris Biopharma
    Clinical, Review, Journal:  Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia. (Pubmed Central) -  Sep 14, 2023   
    Baqsimi achieved a lower mean maximum blood glucose value, which may have implications for the re-establishment of euglycemia. These findings may help support patients, caregivers and health care providers in their decision-making process when discussing various ready-to-use glucagon treatment options.
  • ||||||||||  Zegalogue (dasiglucagon) / Novo Nordisk
    Review, Journal:  Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia. (Pubmed Central) -  Sep 7, 2023   
    This form of glucagon comes in a ready-to-administer, pre-filled syringe, making it easier for caretakers and bystanders to administer in an emergency situation due to the readiness of the medication. The purpose of the paper is to evaluate literature that pertains to the ease of use and patient safety of dasiglucagon HypoPal autoinjector for the management of severe hypoglycemia.
  • ||||||||||  Zegalogue (dasiglucagon) / Novo Nordisk
    Enrollment change, Trial withdrawal:  Micro Glucagon During Exercise in Type 1 Diabetes (clinicaltrials.gov) -  Sep 1, 2023   
    P1,  N=0, Withdrawn, 
    The purpose of the paper is to evaluate literature that pertains to the ease of use and patient safety of dasiglucagon HypoPal autoinjector for the management of severe hypoglycemia. N=20 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Dasiglucagon HypoPal Rescue Pen (dasiglucagon) / Zealand Pharma, Gvoke HypoPen (glucagon auto-injectable rescue pen) / Xeris Biopharma
    Review, Journal:  Managing Severe Hypoglycaemia in Patients with Diabetes: Current Challenges and Emerging Therapies. (Pubmed Central) -  Feb 10, 2023   
    Novel formulations of glucagon include the nasal form, the Gvoke HypoPen which is a ready-to-deliver auto-injector packaged formulation and finally a glucagon analogue, Dasiglucagon...Thus, significant improvements including development of newer insulin analogues, insulin pump therapy, continuous glucose monitoring (CGM), sensor-augmented pump therapy and novel formulations of glucagon have all contributed to reducing and preventing hypoglycaemia in diabetic individuals. However, considerable challenges remain as not all patients have access to diabetes technologies and to the newer glucagon formulations to help reduce and prevent hypoglycaemia.
  • ||||||||||  Zegalogue (dasiglucagon) / Novo Nordisk
    Trial completion, Bariatric surgery:  SHERRY: Treatment of Post-bariatric Hypoglycaemia (clinicaltrials.gov) -  Feb 2, 2023   
    P2,  N=24, Completed, 
    Initiation date: Jul 2022 --> Feb 2023 Active, not recruiting --> Completed
  • ||||||||||  Journal:  Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons. (Pubmed Central) -  Dec 23, 2022   
    The aims of this study were to evaluate the use of glucagon in persons with type 1 diabetes in several countries, and to investigate if the availability of new ready-to-use glucagons (Baqsimi, Gvoke, Zegalogue, years 2019 to 2021) has expanded the overall use of glucagon...The use of glucagon (any type) remains low, approximately 1/10 of persons with type 1 diabetes. We conclude that use of glucagon is scarce in most countries, and so far has not been expanded by new ready-to-use glucagons such as the ones considered in this study.
  • ||||||||||  Dasiglucagon HypoPal Rescue Pen (dasiglucagon) / Zealand Pharma
    DASIGLUCAGON CORRECTS POSTPRANDIAL HYPOGLYCAEMIA IN ROUX-EN-Y GASTRIC BYPASS-OPERATED INDIVIDUALS (Hall M1) -  Dec 16, 2022 - Abstract #ATTD2023ATTD_340;    
    We conclude that use of glucagon is scarce in most countries, and so far has not been expanded by new ready-to-use glucagons such as the ones considered in this study. CGM-guided self-administration of dasigluca-gon effectively corrected postprandial hypoglycaemia in RYGB-operated individuals and is a promising therapeutic avenue forthe treatment of PBH.
  • ||||||||||  GlucaGen (recombinant glucagon) / Novo Nordisk, Zegalogue (dasiglucagon) / Novo Nordisk
    Trial completion date, Trial initiation date, Trial primary completion date:  STABLE-1: A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System (clinicaltrials.gov) -  Nov 28, 2022   
    P2,  N=12, Not yet recruiting, 
    CGM-guided self-administration of dasigluca-gon effectively corrected postprandial hypoglycaemia in RYGB-operated individuals and is a promising therapeutic avenue forthe treatment of PBH. Trial completion date: Nov 2022 --> Aug 2023 | Initiation date: Sep 2022 --> Jun 2023 | Trial primary completion date: Oct 2022 --> Jul 2023
  • ||||||||||  Dasiglucagon HypoPal Rescue Pen (dasiglucagon) / Zealand Pharma
    Dasiglucagon Treatment Over 21 days in Infants with Congenital Hyperinsulinism Results in Glycaemic Stability and Reduces Requirement for Intravenous Glucose (Rome, Italy) -  Nov 13, 2022 - Abstract #ESPE2022ESPE_1195;    
    The use of continuous subcutaneous infusion of dasiglucagon in a 21-day open-label trial in infants with CHI suggests that dasiglucagon may reduce intravenous glucose requirements, time in hypoglycaemia and enabled discontinuation of intravenous glucose in most infants, thus obviating the need for subtotal pancreatectomy for glycaemic stability. In combination with results from Part 1, these data support the efficacy and safety of DASI as a potential novel treatment for CHI.
  • ||||||||||  Zegalogue (dasiglucagon) / Novo Nordisk
    Enrollment closed, Trial completion date, Bariatric surgery:  SHERRY: Treatment of Post-bariatric Hypoglycaemia (clinicaltrials.gov) -  Nov 2, 2022   
    P2,  N=24, Active, not recruiting, 
    Dasiglucagon has the potential to be an effective, safe, and well tolerated novel treatment for newborns with CHI. Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Dec 2022
  • ||||||||||  Dasiglucagon HypoPal Rescue Pen (dasiglucagon) / Zealand Pharma
    Journal:  Dasiglucagon for treating severe hypoglycemia in patients with diabetes. (Pubmed Central) -  Sep 10, 2022   
    Clinical studies have shown that dasiglucagon rapidly and effectively increased insulin-induced hypoglycemia in patients with diabetes. Dasiglucagon was well tolerated and the common adverse events included nausea and vomiting.
  • ||||||||||  Dasiglucagon HypoPal Rescue Pen (dasiglucagon) / Zealand Pharma
    Journal:  Dasiglucagon: A Novel Ready-to-Use Treatment for Severe Hypoglycemia. (Pubmed Central) -  Jul 22, 2022   
    Dasiglucagon offers safe and effective treatment for severe hypoglycemia in patients aged 6 years and older. The stability of dasiglucagon in aqueous solution provides an additional option for emergency glucagon treatment that does not require reconstitution prior to administration.
  • ||||||||||  Zegalogue (dasiglucagon) / Novo Nordisk
    Trial completion date, Trial primary completion date:  Micro Glucagon During Exercise in Type 1 Diabetes (clinicaltrials.gov) -  May 20, 2022   
    P1,  N=20, Not yet recruiting, 
    Low-dose dasiglucagon safely and effectively prevented insulin-induced hypoglycemia with a faster glucose-elevating profile than oral glucose. Trial completion date: Jun 2021 --> Jun 2024 | Trial primary completion date: Apr 2021 --> Apr 2024
  • ||||||||||  Baqsimi (glucagon intranasal dry powder) / Eli Lilly, Dasiglucagon HypoPal Rescue Pen (dasiglucagon) / Zealand Pharma, Gvoke HypoPen (glucagon auto-injectable rescue pen) / Xeris Pharma
    Indirect Treatment Comparison (ITC) of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia: Baqsimi, Gvoke, and Zegalogue (Poster Hall (Halls D-E); Board No. 375) -  May 11, 2022 - Abstract #ADA2022ADA_1816;    
    Baqsimi had comparable efficacy with Gvoke and with Zegalogue (Table), and all 3 treatments achieved high treatment success (>98%) in adults and children with diabetes. In adults, results from the combined T1D and T2D analysis were consistent with the T1D analysis, except a statistically significant faster time achieving treatment success observed for Baqsimi vs.